GLP-1 Market
LLY $1123.00 ▼ -0.1% NVO $44.01 ▼ -1.2% PFE $27.65 ▼ -0.5% VKTX $32.13 ▼ -1.7% KLRA $14.91 ▲ +0.5% GPCR $39.55 ▼ -4.1% RHHBY $53.19 ▼ -0.4% HIMS $27.44 ▼ -1.6% WW $14.78 ▼ -1.1%
Delayed · As of 9:20 AM

Empowering you to have better conversations with your doctor.

Subscribe
About this data Sourced primarily from ClinicalTrials.gov — a listing isn't proof of safety or FDA approval.

Pipeline and clinical trial information here comes primarily from ClinicalTrials.gov. A listing on ClinicalTrials.gov means a study has been registered — not that a treatment is proven safe, effective, or FDA-approved. Investigational treatments may never be approved. Who can join a trial is decided only by that trial's own study team.

Not yet reported

GSK189075

Company
GlaxoSmithKline
Mechanism
Mechanism not yet reported
Route
Route not yet reported
Recruiting trials
None currently listed

Efficacy results: Not yet reported

No recruiting studies currently listed

See all studies for this drug

Data source: ClinicalTrials.gov · trial data as of Sep 11, 2026

Trial details
  • Completed NCT NCT00291356

    GSK189075, GW869682 Or Placebo In Type 2 Diabetic Patients

    Not yet reported GlaxoSmithKline 45 participants Est. completion 2006-05 3 sites
    Type 2 diabetes Other conditions: Non-Insulin-Dependent Diabetes Mellitus
    View official trial listing →
  • Completed NCT NCT00376038

    Drug Interactions From Simultaneous Administration Of Metformin And GSK189075 To Subjects With Type 2 Diabetes

    Not yet reported GlaxoSmithKline 13 participants Est. completion 2006-10 1 site
    Type 2 diabetes
    View official trial listing →
  • Completed NCT NCT00494767

    Investigation Of Weight Loss And Body Composition Changes After Dosing With Either Placebo Or One Of Two Active Drugs

    Not yet reported GlaxoSmithKline 27 participants Est. completion 2007-06-07 1 site Stand-alone
    Type 2 diabetes Other conditions: Obesity
    View official trial listing →
  • Completed NCT NCT00495469

    Dose-Ranging Study In Subjects With Type 2 Diabetes Mellitus Who Are Treatment-Naive

    Not yet reported GlaxoSmithKline 250 participants Est. completion 2008-06-05 157 sites Stand-alone
    Type 2 diabetes
    View official trial listing →
  • Completed NCT NCT00500331

    Dose-Ranging Study in Treatment Naive Type 2 Diabetes Mellitus(T2DM)

    Not yet reported GlaxoSmithKline 334 participants Est. completion 2008-02-14 136 sites Stand-alone
    Type 2 diabetes
    View official trial listing →
  • Completed NCT NCT00501397

    A Study of the Effects of Ketoconazole Taken Orally Has on the PK Profiles of a Dose of GSK189075 in Healthy Volunteers

    Not yet reported GlaxoSmithKline 22 participants 1 site
    Type 2 diabetes
    View official trial listing →
  • Completed NCT NCT00501462

    A Comparison Of Study Drug Blood Levels After One Dose Of GSK189075 In Subjects With Normal And Reduced Kidney Function

    Not yet reported GlaxoSmithKline 29 participants Est. completion 2008-03 4 sites
    Type 2 diabetes Other conditions: Renal Insufficiency
    View official trial listing →
  • Completed NCT NCT00501683

    A Single Dose Of GSK189075 Taken By Mouth Containing Small Amounts Of Radioactivity Studied In Healthy Male Volunteers

    Not yet reported GlaxoSmithKline 8 participants 1 site
    Type 2 diabetes
    View official trial listing →
  • Completed NCT NCT00501930

    A Study to Evaluate and Study Drug Levels in Blood Plasma When Giving High Doses of GSK189075 to Healthy Volunteers

    Not yet reported GlaxoSmithKline 12 participants 1 site
    Type 2 diabetes
    View official trial listing →
  • Completed NCT NCT00504816

    A Study of the Effects of GSK189075 on PK Profiles of an Oral Contraceptive Pill When Given to Healthy Female Volunteers

    Not yet reported GlaxoSmithKline 22 participants Est. completion 2008-04 1 site Stand-alone
    Type 2 diabetes
    View official trial listing →
  • Completed NCT NCT00519480

    A Study To Assess The Safety And Tolerability Of GSK189075 When Given With A Total Daily Dose Of >/ 2000mg of Metformin

    Not yet reported GlaxoSmithKline 50 participants Est. completion 2008-04-01 4 sites Stand-alone
    Type 2 diabetes
    View official trial listing →
  • Completed NCT NCT00532610

    A Study to Compare the Effect on Heart Rhythm of 3 Days of GSK189075, Placebo, or Moxifloxacin in Healthy Adults

    Not yet reported GlaxoSmithKline 78 participants Est. completion 2008-02 1 site
    Type 2 diabetes
    View official trial listing →
  • Completed NCT NCT00559884

    A Study to Compare the Safety and Drug Levels in Blood When Using Various Forms of GSK189075 Given to Healthy Subjects

    Not yet reported GlaxoSmithKline 36 participants 1 site
    Type 2 diabetes
    View official trial listing →
  • Completed NCT NCT00575159

    A Study to Assess the Safety of Single Doses of GSK189075 in Subjects With Type 1 Diabetes Mellitus

    Not yet reported GlaxoSmithKline 10 participants Est. completion 2008-12-18 1 site Stand-alone
    Other conditions: Diabetes Mellitus, Type 1
    View official trial listing →
  • Completed NCT NCT00625859

    A Study to Assess the Safety of Repeated Doses of GSK189075 and WELLBUTRIN SR in Healthy Male Subjects

    Not yet reported GlaxoSmithKline 27 participants Est. completion 2008-04-10 1 site Stand-alone
    Type 2 diabetes
    View official trial listing →
  • Completed NCT NCT00671424

    A Study To Compare Effects Of GSK189075 In Combination With Either Furosemide Or Hydrochlorothiazide

    Not yet reported GlaxoSmithKline 48 participants Est. completion 2008-05 1 site
    Type 2 diabetes
    View official trial listing →
Efficacy history

Not yet reported.

Safety

Not yet reported.

Sources
Related On The Pen coverage

No related coverage yet.

This drug may be investigational and not yet approved for any use. Whether someone can join a clinical trial is determined only by that trial's own study team — On The Pen does not determine eligibility. Information here can change; always confirm current details on the official ClinicalTrials.gov listing or with the sponsor.